

# Validation of predictors for oral anticoagulant medication choice using EMR data

**First published:** 03/01/2017

**Last updated:** 03/01/2017

Study

Planned

## Administrative details

### PURI

<https://redirect.ema.europa.eu/resource/16315>

---

### EU PAS number

EUPAS16314

---

### Study ID

16315

---

### DARWIN EU® study

No

---

### Study countries

☐ United States

---

## Study description

This validation study seeks to ascertain a select set of covariates in electronic medical records (EMRs) linked to a subset of patients within the insurance claims data in order to assess the potential for unmeasured confounding in observational studies based on insurance claims databases only.

---

## Study status

Planned

# Research institutions and networks

## Institutions

**Brigham and Women's Hospital**

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

## Contact details

### Study institution contact

Sebastian Schneeweiss

**Study contact**

[sschneeweiss@partners.org](mailto:sschneeweiss@partners.org)

### Primary lead investigator

Sebastian Schneeweiss

## Study timelines

### **Date when funding contract was signed**

Planned: 01/06/2012

Actual: 01/06/2012

---

### **Study start date**

Planned: 06/01/2017

---

### **Data analysis start date**

Planned: 06/01/2017

---

### **Date of final study report**

Planned: 30/09/2017

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Boehringer Ingelheim

## Regulatory

### **Was the study required by a regulatory body?**

No

---

## Is the study required by a Risk Management Plan (RMP)?

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Other

#### **If 'other', further details on the scope of the study**

Validation Study

#### **Main study objective:**

To identify select clinical covariates from electronic medical records that might be associated with initiation of oral anticoagulant medications. To quantify the association between EMR-based clinical characteristics and patterns of insurance claims. To assess the potential for unmeasured confounding in dabigatran vs warfarin comparative effectiveness and safety studies based on claims data

### Study Design

## Non-interventional study design

Cohort

Other

---

## Non-interventional study design, other

Validation Study

# Study drug and medical condition

## Anatomical Therapeutic Chemical (ATC) code

(B01A) ANTITHROMBOTIC AGENTS

ANTITHROMBOTIC AGENTS

---

## Medical condition to be studied

Atrial fibrillation

# Population studied

## Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## Estimated number of subjects

60000

# Study design details

## Outcomes

Obesity Smoking Alcohol consumption Abnormal renal function Bleeding history or predisposition Renal function (estimated GFR) Serum Creatinine Abnormal liver function, Duration of atrial fibrillation History of adherence Hypertension Uncontrolled Hypertension (for HAS-BLED) Congestive heart failure Prior TIA Diabetes Hyperlipidaemia HAS-BLED Score Use of anti-platelets or NSAIDs (needed for HAS-BLED)

---

## Data analysis plan

Analyses will characterize patients with EMR and compare them to those without EMR to assess representativeness of the linked sample. To identify covariates from EMR that might be associated with initiation of oral anticoagulants, the presence of EMR-based clinical characteristics among initiators of dabigatran and warfarin will be described. To quantify the association between EMR-based clinical characteristics and patterns of insurance claims, a prediction algorithm will be estimated using a regression model that uses each of the EMR characteristic as the model outcome and all available claims-based covariates as predictors. To assess the potential for unmeasured confounding, logistic regression models that predict exposure (dabigatran vs. warfarin) with claims data only, EMR data only, and both, will be fitted.

## Data management

### Data sources

#### Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

## Use of a Common Data Model (CDM)

### **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No